Quintiles, the world’s largest provider of biopharmaceutical services, has introduced a new patient enrollment offering designed to accelerate study startup and reduce costs for oncology clinical trials by opening investigative sites for studies only after they have identified a qualified patient. With the model, called Precision Enrollment, Quintiles has built a network of 80 oncology sites across the U.S. that can pre-identify patients based on study and biomarker criteria using electronic health records (EHRs) and other secondary data sources.
CRO industry consolidation continues as Amulet acquires SynteractHCR
The latest deal in a steady string of mergers and acquisitions in the CRO industry closed at the end of last month, when Amulet Capital Partners bought out SynteractHCR. SynteractHCR ranks as a top 20 global, full-service CRO focused on phase I to IV clinical trials for emerging to mid-sized biopharma clients in the U.S., Europe and Asia. Based in San Diego, the organization serves 700,000-plus patients, employs some 800 staffers in 21 countries and has contributed to more than 230 product approvals.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.
